Merck's $31.7 Billion Keytruda Machine Has Two Years Before the Patent Cliff — Here's the Replacement Playbook

Merck is executing a high-stakes portfolio transformation ahead of Keytruda's 2028 patent expiration, spending ~$26 billion on acquisitions in 18 months while its sac-TMT ADC just became the first antibody-drug conjugate to beat a checkpoint inhibitor combo in first-line lung cancer. The stock is up 56% YoY as investors bet the transition math works.

MRK · Health Care · May 21, 2026

S&P 500 Position

Within Health Care, Merck sits behind Eli Lilly (~$850B) and UnitedHealth Group (~$450B) but ahead of AbbVie (~$260B) and Johnson & Johnson (~$350B, diversified). The competitive dynamic in oncology pits Merck's Keytruda franchise against Bristol-Myers Squibb's Opdivo/Yervoy, AstraZeneca's Imfinzi/Tagrisso combinations, and Roche's Tecentriq. In the ADC space specifically, sac-TMT competes directly with Gilead's Trodelvy and AstraZeneca/Daiichi Sankyo's Enhertu and Datroway.

Index Weight: Data unavailable | Rank: Top 20–25 in S&P 500 by market cap (~$270 billion), making it the second-largest pure-play pharma company after Eli Lilly

Company Overview

Merck is a $65 billion-revenue pharmaceutical company running a controlled demolition-and-rebuild of its revenue base. Keytruda, the anti-PD-1 checkpoint inhibitor that generated $31.7 billion in 2025 — nearly half of total sales — loses U.S. IV patent exclusivity in 2028. Every strategic decision the company makes right now is a function of that deadline. The subcutaneous reformulation, Keytruda Qlex (approved September 2025), is the primary defense: switch patients to a new formulation with fresh patent protections before biosimilar manufacturers like Amgen, Samsung Bioepis, and Bio-Thera Solutions can enter the IV market. Qlex contributed only $40 million in its first partial year, but the conversion ramp is the single most important operational metric for Merck over the next 24 months. Beyond the reformulation play, Merck has been on an acquisition spree that reshapes the pipeline. Three deals totaling ~$26 billion closed between late 2025 and May 2026: Verona Pharma ($10B, adding the COPD drug Ohtuvayre), Cidara Therapeutics ($9.2B, antifungal and anti-influenza assets), and Terns Pharmaceuticals ($6.7B, adding TERN-701, an allosteric BCR::ABL1 inhibitor for CML). The company claims over 20 new growth drivers with a combined non-risk-adjusted commercial opportunity exceeding $70 billion by the mid-2030s. The two assets with the clearest near-term trajectories are Winrevair (sotatercept) for pulmonary arterial hypertension, already at a $2.1 billion annualized run rate, and sac-TMT, a TROP2-directed ADC partnered with Kelun-Biotech that just posted a landmark Phase 3 win in first-line NSCLC. The competitive positioning is unusual: Merck is simultaneously the dominant oncology franchise (Keytruda remains the world's best-selling drug) and one of the most exposed large-cap pharma companies to patent-cliff risk. The market is pricing in confidence — MRK trades at 15x earnings with a 56% YoY stock gain — but the execution window is narrow. If the Qlex conversion stalls, or if sac-TMT's 17 ongoing Phase 3 trials produce mixed results, the math changes fast.

Products & Revenue

Merck's revenue is overwhelmingly pharmaceutical, with Keytruda alone representing nearly half of worldwide sales. The company operates two reportable segments: Pharmaceutical (89.4% of revenue) and Animal Health (9.8%). Within pharma, the concentration risk is extreme — Keytruda at $31.7 billion dwarfs the next-largest franchise, Gardasil/Gardasil 9 at $5.2 billion, which itself collapsed 39% in 2025 due to China channel destocking (zero China sales in Q4 2025). The emerging growth assets — Winrevair ($1.4B) and Capvaxive ($759M) — are scaling but remain small relative to the Keytruda base that must eventually be replaced.

KEYTRUDA / KEYTRUDA QLEX (48.8%): Anti-PD-1 monoclonal antibody approved across 40+ tumor types. Qlex is the subcutaneous reformulation designed to extend franchise life beyond the 2028 IV patent cliff. Q1 2026 sales hit $8 billion (+12% YoY).

GARDASIL / GARDASIL 9 (8.0%): Recombinant HPV vaccine covering up to 9 HPV types. Revenue declined 39% in 2025 to $5.2 billion, driven by inventory digestion and demand normalization in China following the Zhifei distribution model reset.

WINREVAIR (sotatercept) (2.2%): First-in-class activin signaling inhibitor for PAH — the first approved disease-modifying therapy in the space. Hit $1.4 billion in its first full year (2025); Q1 2026 at $525 million implies a $2.1 billion annualized run rate. Peak sales estimated at $5–7 billion.

CAPVAXIVE (1.2%): 21-valent pneumococcal conjugate vaccine targeting adults, designed to cover serotypes not in Pfizer's Prevnar 20. Generated $759 million in 2025, its first significant commercial year.

Animal Health (9.8%): Livestock and companion animal pharmaceuticals, vaccines, and digital health products. Generated $6.4 billion in 2025. Includes the Bravecto parasiticide franchise and aquaculture vaccines.

Other Pharmaceutical (Januvia, Lagevrio, Welireg, pipeline) (~30%): Includes legacy diabetes franchise (Januvia/Janumet, facing generic erosion), Lagevrio (molnupiravir for COVID-19), Welireg (belzutifan for RCC), and recently acquired assets like Ohtuvayre (ensifentrine for COPD from Verona Pharma).

Based on FY2025 results per Merck 8-K filed February 2026 with the SEC. Q1 2026 data from 10-Q filed May 2026.

Leadership

Robert M. Davis

CEO since 2021. Davis has served as Chairman, CEO, and President since 2021, having previously been CFO and EVP of Global Services. He is an engineer by training (mechanical engineering, Villanova; MBA, Wharton) who spent the early part of his career at Baxter International. His strategic bet is clear: spend aggressively on acquisitions and pipeline diversification now, while Keytruda cash flows are at peak, to build a post-2028 portfolio that can sustain the revenue base.

Dean Li, EVP and President, Merck Research Laboratories: Oversees all R&D operations including the 18 positive Phase 3 readouts in 2025 and the 17 ongoing sac-TMT Phase 3 studies. Former physician-scientist at the University of Utah, with a background in vascular biology and genomics.

Caroline Litchfield, CFO and Executive Vice President: Manages the capital allocation strategy behind ~$26 billion in acquisitions over 18 months while maintaining investment-grade credit (debt/equity at 0.96). Key voice on the Terns Pharmaceuticals and Cidara deal structuring.

Jannie Oosthuizen, EVP and President, Oncology & MSD International: Leads the global commercial strategy for Keytruda, the Qlex subcutaneous conversion campaign, and international launch sequencing for Winrevair. Runs the largest business unit by revenue.

The AI Angle

Open-Source Molecular AI for Industrial Drug Discovery

Merck's AI strategy is research-infrastructure-first rather than product-facing. The most tangible output is KERMT, an open-source small-molecule drug discovery foundation model released in December 2025 in partnership with NVIDIA. KERMT is pretrained on more than 11 million molecules and fine-tuned for industrial drug discovery workflows — molecular property prediction, ADMET profiling, and lead optimization. Using NVIDIA's compute infrastructure, Merck achieved 2.2x faster fine-tuning and 2.9x faster inference compared to the baseline GROVER model, which is meaningful when you're screening millions of candidate compounds. The NVIDIA partnership is the build layer; the Mayo Clinic collaboration announced in February 2026 is the clinical data layer. That agreement applies AI and advanced analytics to multimodal clinical data — imaging, genomics, EHR records — to support drug discovery and precision medicine. The goal is not just target identification but patient stratification: using AI to determine which patients will respond to which therapies, a prerequisite for the kind of biomarker-driven trial designs that Keytruda's PD-L1 expression scoring pioneered. Merck's approach is distinctly different from the pure-play AI drug discovery companies (Recursion, Insilico Medicine) or the fully vertically integrated models (Google DeepMind's AlphaFold). Merck is treating AI as an accelerant layer on top of its existing wet-lab and clinical infrastructure rather than a replacement for it. The open-sourcing of KERMT signals confidence that the competitive moat is in proprietary biological data and clinical execution, not in the model architecture itself. The risk profile is standard for pharma AI: the gap between in-silico molecular property predictions and actual clinical outcomes remains large. No AI-discovered molecule from Merck has entered Phase 3 trials yet based on available data. The near-term value is in cycle-time compression — getting from target to IND faster — rather than in discovering fundamentally new biology.

Financial Snapshot

Revenue (TTM): $65.0B — TTM (period ending Dec 31, 2025) | Net Income: $18.3B net income (TTM)

Margins: Net margin 28.1%; gross and operating margin data unavailable from provided filings

Merck's financial profile reflects a company deliberately front-loading acquisition spending while Keytruda cash flows peak. FY2025 GAAP EPS was $7.28 (non-GAAP $8.98); Q1 2026 showed a GAAP loss of $1.28/share due to the $9.0 billion Cidara acquisition charge, but revenue beat consensus by ~$400 million. FY2026 guidance of $65.8–67.0 billion revenue and $5.04–5.16 non-GAAP EPS (midpoint raised) signals management confidence in the near-term trajectory. The 0.96 debt/equity ratio is worth watching — three deals totaling $26 billion will pressure the balance sheet if the acquired assets underperform.

1-Year Performance

$115.88 current price, up 56% year-over-year — a remarkable reversal from the LOE-driven pessimism that weighed on shares through mid-2025

The 56% YoY rally reflects three catalysts: Winrevair's faster-than-expected commercial ramp removing concerns about post-Keytruda revenue replacement, the sac-TMT Phase 3 data providing a credible next-generation oncology franchise, and Q1 2026 earnings beating consensus on both top and bottom lines. The median analyst target of $130 (range $100–$150) suggests the Street sees ~12% upside but remains cautious — 18 Buys versus 11 Holds and zero Sells. Citi's Neutral at $125 captures the wait-and-see sentiment: the thesis works if clinical catalysts continue delivering.

Recent News

Fun Fact: Sac-TMT (MK-2870/SKB264), the TROP2-directed ADC that just posted Merck's biggest clinical win of 2026, uses a drug-to-antibody ratio (DAR) of 7.4 — nearly double the DAR of most competing ADCs like Enhertu (DAR ~8) and far above Trodelvy (DAR ~7.6). The key differentiator is a bifunctional linker engineered to be irreversibly bonded to the antibody in circulation but pH-sensitive in the lysosome, releasing a belotecan-derivative topoisomerase I inhibitor payload only inside tumor cells. This is not Merck's own chemistry — it was developed by Kelun-Biotech in Chengdu, China, and Merck licensed global rights, then brought in Blackstone Life Sciences to co-fund development. The financing structure itself is unusual: a strategic investor partially bankrolling a Phase 3 program for a pharma company with $65 billion in revenue.